Jardiance's Label Expansion Will Change Diabetes Management
US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Boehringer Ingelheim agreement with data analytics firm Inovalon and health care consultancy Avalere will support outcomes-based coverage deals.
India’s streamlined clinical trial approvals process appears to have made some gains, but top industry experts tell Pink Sheet how the non-standardized approach of Subject Expert Committees is a “major handicap” for applicants.